What’s in store for Healthcare with the new government? Picture: Getty Image
Health & Biotech
The ALP election win sparked a mini rally in ASX-listed aged care stocks on the first day of trading this week.
Estia Healthcare (ASX:EHE), one of Australia’s larger aged care operators with 68 homes across the country, rose more than 8% on Monday.
As part of its election campaign, Labor has promised an additional $2.5 billion in aged care funding.
That’s an addition to the $18.8 billion, five-year aged care reform program already announced in this year’s Federal Budget.
The new plan would require every aged care facility in the country to have a registered nurse on site at all hours, as well as setting higher meal standards for residents.
In primary healthcare, the Albanese government has also pledged an extra $970 million, including $750 million for the “Strengthening Medicare” taskforce fund.
The taskforce is expected to deliver improved patient access to General Practice, including after-hours GP access, and greater patient affordability.
The Medicare reimbursement program has already received around $31 billion in the 2022-23 Fed Budget, a $7.3bn increase from the previous year – reflecting the increased use of doctors and telehealth during the pandemic.
Former Treasurer Josh Frydenberg noted that telehealth has been the most significant reform to Medicare since its creation, and was “the key landmark reform” within the government’s primary healthcare 10-year plan.
Since March 2020, more than 100 million telehealth services have been delivered to 17 million people in Australia.
Meanwhile the new PM is yet to announce his full cabinet, but the most obvious choice for the next Federal Health Minister role is Mark Butler.
Butler has been the Shadow Minister for Health and Ageing portfolio since January 2021, after spending five years as a climate spokersperson prior to that.
| CODE | COMPANY | PRICE | 1 WEEK RETURN % | 1 MONTH RETURN % | 1 YEAR RETURN % | MARKET CAP |
|---|---|---|---|---|---|---|
| ALT | Analytica Limited | 0.0015 | 50% | 0% | -40% | $6,920,701.69 |
| IMU | Imugene Limited | 0.205 | 24% | -9% | -49% | $1,199,003,534.24 |
| CTE | Cryosite Limited | 0.735 | 23% | 25% | 104% | $35,875,028.81 |
| ADR | Adherium Ltd | 0.011 | 22% | 10% | -35% | $24,290,762.01 |
| ADO | Anteotech Ltd | 0.1075 | 14% | -17% | -66% | $198,752,480.20 |
| MEB | Medibio Limited | 0.004 | 14% | -11% | -47% | $8,389,465.43 |
| ONE | Oneview Healthcare | 0.245 | 14% | 9% | -26% | $127,044,628.24 |
| CDX | Cardiex Limited | 0.35 | 13% | -5% | -49% | $38,483,795.00 |
| CPH | Creso Pharma Ltd | 0.056 | 12% | -7% | -64% | $72,592,380.11 |
| M7T | Mach7 Tech Limited | 0.62 | 12% | -15% | -42% | $142,101,498.56 |
| BDX | Bcaldiagnostics | 0.1 | 11% | -5% | 0% | $13,209,471.00 |
| IIQ | Inoviq Ltd | 0.565 | 11% | -16% | -77% | $51,990,566.63 |
| IDT | IDT Australia Ltd | 0.155 | 11% | -6% | -47% | $38,563,487.52 |
| SHG | Singular Health | 0.16 | 10% | -18% | -43% | $10,446,251.04 |
| PTX | Prescient Ltd | 0.165 | 10% | 27% | 57% | $107,916,030.59 |
| CHM | Chimeric Therapeutic | 0.125 | 9% | -7% | -55% | $35,075,244.84 |
| CYP | Cynata Therapeutics | 0.38 | 9% | -3% | -37% | $54,445,105.72 |
| TD1 | Tali Digital Limited | 0.0065 | 8% | -41% | -81% | $7,961,145.83 |
| ARX | Aroa Biosurgery | 0.85 | 6% | -3% | -28% | $287,888,334.72 |
| DVL | Dorsavi Ltd | 0.018 | 6% | -14% | -38% | $6,369,863.13 |
| CGS | Cogstate Ltd | 1.745 | 6% | -22% | 109% | $303,336,246.50 |
| RSH | Respiri Limited | 0.038 | 6% | -36% | -60% | $28,879,861.15 |
| UBI | Universal Biosensors | 0.49 | 5% | -34% | -27% | $91,071,748.88 |
| VLS | Vita Life Sciences.. | 1.83 | 5% | -13% | 66% | $97,241,829.96 |
| BWX | BWX Limited | 1.395 | 4% | -28% | -74% | $223,527,784.27 |
| SDI | SDI Limited | 0.845 | 4% | 3% | -1% | $101,035,700.50 |
| AHC | Austco Healthcare | 0.1 | 4% | -20% | 2% | $28,708,566.90 |
| KZA | Kazia Therapeutics | 0.78 | 4% | -28% | -34% | $105,775,127.14 |
| IRX | Inhalerx Limited | 0.085 | 4% | -26% | -7% | $14,319,691.35 |
| HCT | Holista CollTech Ltd | 0.03 | 3% | -25% | -43% | $7,434,425.35 |
| DXB | Dimerix Ltd | 0.15 | 3% | -3% | -39% | $48,131,049.90 |
| AC8 | Auscann Grp Hlgs Ltd | 0.061 | 3% | -9% | -45% | $26,873,373.71 |
| PBP | Probiotec Limited | 2.29 | 3% | -5% | 13% | $186,230,599.74 |
| CYC | Cyclopharm Limited | 1.35 | 3% | -11% | -46% | $126,056,011.05 |
| ICR | Intelicare Holdings | 0.077 | 3% | -23% | -70% | $6,651,280.33 |
| MDC | Medlab Clinical Ltd | 0.079 | 3% | -25% | -59% | $26,689,702.34 |
| IMC | Immuron Limited | 0.1025 | 3% | -11% | -38% | $23,349,330.47 |
| TLX | Telix Pharmaceutical | 4.23 | 2% | -5% | 6% | $1,323,920,496.00 |
| MVF | Monash IVF Group Ltd | 1.075 | 2% | -13% | 26% | $418,857,453.00 |
| TRP | Tissue Repair | 0.27 | 2% | -23% | 0% | $12,630,695.85 |
| BNO | Bionomics Limited | 0.065 | 2% | -2% | -68% | $87,967,798.36 |
| CAJ | Capitol Health | 0.335 | 2% | 0% | -7% | $349,142,866.52 |
| IMM | Immutep Ltd | 0.385 | 1% | 18% | -32% | $333,502,328.78 |
| PAR | Paradigm Bio. | 1.125 | 1% | -18% | -52% | $261,735,164.25 |
| RHY | Rhythm Biosciences | 1.18 | 1% | -16% | 10% | $256,897,694.40 |
| GSS | Genetic Signatures | 1.295 | 0% | -3% | 9% | $185,684,864.82 |
| BXN | Bioxyne Ltd | 0.014 | 0% | -18% | -36% | $8,962,035.57 |
| AMT | Allegra Orthopaedics | 0.18 | 0% | -5% | -28% | $18,802,656.54 |
| RNO | Rhinomed Ltd | 0.175 | 0% | -15% | 10% | $50,000,946.45 |
| TSN | The Sust Nutri Grp | 0.14 | 0% | -13% | -70% | $16,884,893.90 |
| ATX | Amplia Therapeutics | 0.12 | 0% | -8% | -46% | $23,262,480.12 |
| SCU | Stemcell United Ltd | 0.014 | 0% | 0% | -22% | $14,696,980.89 |
| IVX | Invion Ltd | 0.012 | 0% | -17% | 20% | $76,998,163.73 |
| ICS | ICSGlobal Limited | 0.575313 | 0% | 0% | -1% | $6,054,604.94 |
| FFC | Farmaforce Ltd | 0.035 | 0% | 0% | -46% | $4,573,834.30 |
| AVE | Avecho Biotech Ltd | 0.016 | 0% | -16% | 0% | $29,405,000.42 |
| PIQ | Proteomics Int Lab | 0.97 | 0% | -13% | -12% | $107,819,992.50 |
| EZZ | EZZ Life Science | 0.36 | 0% | -1% | -26% | $4,593,600.00 |
| PAB | Patrys Limited | 0.021 | 0% | -9% | -22% | $43,196,994.90 |
| OPT | Opthea Limited | 1.29 | 0% | 31% | -12% | $475,118,028.00 |
| OVN | Oventus Medical Ltd | 0.021 | 0% | -45% | -83% | $4,834,530.70 |
| GTG | Genetic Technologies | 0.0035 | 0% | -22% | -59% | $27,701,895.43 |
| OSX | Osteopore Limited | 0.175 | 0% | -13% | -65% | $20,521,941.65 |
| PAL | Palla Pharma Ltd | 0.295 | 0% | 0% | -24% | $47,764,383.09 |
| OSP | Osprey Med Inc | 0.2 | 0% | -20% | -88% | $5,131,708.40 |
| IBX | Imagion Biosys Ltd | 0.042 | 0% | -26% | -58% | $45,969,959.89 |
| LCT | Living Cell Tech. | 0.005 | 0% | -38% | -52% | $5,141,818.62 |
| DOC | Doctor Care Anywhere | 0.215 | 0% | -20% | -73% | $48,852,323.65 |
| NXS | Next Science Limited | 0.84 | -1% | 0% | -53% | $176,690,378.76 |
| SOM | SomnoMed Limited | 1.47 | -1% | -24% | -31% | $121,656,193.05 |
| VHT | Volpara Health Tech | 0.72 | -1% | -18% | -41% | $181,393,258.32 |
| PXS | Pharmaxis Ltd | 0.085 | -1% | -15% | 4% | $46,109,545.69 |
| BOT | Botanix Pharma Ltd | 0.08 | -1% | -1% | 5% | $77,851,365.92 |
| VTI | Vision Tech Inc | 0.39 | -1% | -20% | -68% | $9,371,918.40 |
| HGV | Hygrovest Limited | 0.063 | -2% | 0% | -20% | $14,487,101.06 |
| EXL | Elixinol Wellness | 0.047 | -2% | -15% | -68% | $14,864,481.84 |
| CBL | Control Bionics | 0.235 | -2% | -36% | -63% | $11,827,762.91 |
| BIT | Biotron Limited | 0.092 | -2% | 19% | 70% | $63,173,944.17 |
| ZLD | Zelira Therapeutics | 1.35 | -2% | -39% | -83% | $13,024,877.76 |
| IPD | Impedimed Limited | 0.089 | -2% | -32% | -29% | $158,231,296.42 |
| RGS | Regeneus Ltd | 0.044 | -2% | -23% | -54% | $13,483,224.22 |
| RAP | Resapp Health Ltd | 0.11 | -2% | 0% | 100% | $94,511,678.47 |
| NC6 | Nanollose Limited | 0.085 | -2% | -14% | -6% | $12,655,341.28 |
| MEM | Memphasys Ltd | 0.039 | -3% | -35% | -25% | $30,894,955.14 |
| RCE | Recce Pharmaceutical | 0.775 | -3% | -13% | -25% | $135,266,831.43 |
| OCC | Orthocell Limited | 0.37 | -3% | -12% | -26% | $72,937,327.81 |
| ACR | Acrux Limited | 0.071 | -3% | -15% | -49% | $20,214,165.69 |
| HXL | Hexima | 0.32 | -3% | 0% | 88% | $51,116,400.32 |
| CAN | Cann Group Ltd | 0.32 | -3% | -22% | -29% | $115,210,763.25 |
| VBS | Vectus Biosystems | 1.14 | -3% | -12% | 18% | $39,711,248.50 |
| 1AD | Adalta Limited | 0.057 | -3% | -20% | -57% | $17,908,530.52 |
| ANP | Antisense Therapeut. | 0.099 | -3% | -12% | -53% | $65,541,809.84 |
| NTI | Neurotech Intl | 0.056 | -3% | 12% | -3% | $39,071,151.06 |
| ALC | Alcidion Group Ltd | 0.14 | -3% | -30% | -60% | $177,529,667.42 |
| AT1 | Atomo Diagnostics | 0.083 | -3% | -28% | -50% | $47,383,952.25 |
| OIL | Optiscan Imaging | 0.135 | -4% | -7% | -65% | $83,590,056.27 |
| RAC | Race Oncology Ltd | 1.73 | -4% | -28% | -47% | $279,159,618.50 |
| LBT | LBT Innovations | 0.082 | -5% | -1% | 4% | $26,231,926.61 |
| RAD | Radiopharm | 0.195 | -5% | -24% | 0% | $23,125,666.40 |
| RAD | Radiopharm | 0.195 | -5% | -24% | 0% | $23,125,666.40 |
| AN1 | Anagenics Limited | 0.037 | -5% | -18% | -38% | $8,177,788.21 |
| LDX | Lumos Diagnostics | 0.255 | -6% | -27% | 0% | $38,448,129.39 |
| EPN | Epsilon Healthcare | 0.034 | -6% | -17% | -77% | $7,931,682.26 |
| ATH | Alterity Therap Ltd | 0.016 | -6% | -16% | -45% | $38,509,993.25 |
| ILA | Island Pharma | 0.15 | -6% | -21% | -56% | $6,486,949.20 |
| NOX | Noxopharm Limited | 0.225 | -6% | -26% | -61% | $65,753,538.75 |
| ACW | Actinogen Medical | 0.071 | -7% | -25% | -26% | $126,354,711.01 |
| ALA | Arovella Therapeutic | 0.034 | -7% | -19% | -11% | $22,774,397.68 |
| ZNO | Zoono Group Ltd | 0.195 | -7% | -19% | -72% | $33,282,341.00 |
| MVP | Medical Developments | 2.66 | -7% | -25% | -47% | $199,654,159.60 |
| NEU | Neuren Pharmaceut. | 3.45 | -8% | -12% | 176% | $443,399,179.52 |
| CU6 | Clarity Pharma | 0.425 | -8% | -21% | 0% | $74,641,595.39 |
| PAA | Pharmaust Limited | 0.084 | -8% | -9% | -9% | $26,620,640.17 |
| GLH | Global Health Ltd | 0.23 | -8% | -19% | -68% | $13,029,446.41 |
| MXC | Mgc Pharmaceuticals | 0.021 | -9% | -9% | -57% | $60,022,464.74 |
| MDR | Medadvisor Limited | 0.2 | -9% | -23% | -30% | $76,157,987.80 |
| S66 | Star Combo | 0.135 | -10% | -31% | -47% | $18,157,902.44 |
| 4DX | 4Dmedical Limited | 0.63 | -10% | -18% | -48% | $131,642,130.69 |
| OSL | Oncosil Medical | 0.051 | -11% | -18% | -35% | $47,106,537.88 |
| PSQ | Pacific Smiles Grp | 1.615 | -11% | -28% | -35% | $257,724,829.87 |
| PNV | Polynovo Limited | 1.155 | -11% | 12% | -56% | $784,100,332.14 |
| MX1 | Micro-X Limited | 0.16 | -11% | -18% | -52% | $73,832,682.56 |
| NSB | Neuroscientific | 0.2 | -11% | -30% | -32% | $28,694,328.60 |
| PYC | PYC Therapeutics | 0.071 | -11% | -25% | -49% | $225,845,753.31 |
| AGH | Althea Group | 0.115 | -12% | -32% | -70% | $36,340,561.09 |
| EYE | Nova EYE Medical Ltd | 0.22 | -12% | -15% | -31% | $32,027,554.02 |
| AHK | Ark Mines Limited | 0.33 | -12% | -39% | 871% | $10,992,333.99 |
| PGC | Paragon Care Limited | 0.31 | -13% | -19% | 35% | $202,944,505.37 |
| PCK | Painchek Ltd | 0.034 | -13% | -17% | -50% | $40,744,972.76 |
| RHT | Resonance Health | 0.081 | -14% | -33% | -57% | $37,329,010.46 |
| TRU | Truscreen | 0.055 | -15% | -10% | -24% | $19,957,643.92 |
| CMP | Compumedics Limited | 0.165 | -18% | -41% | -59% | $29,231,886.42 |
| IHL | Incannex Healthcare | 0.4 | -21% | -6% | 54% | $530,785,963.22 |
| JTL | Jayex Technology Ltd | 0.007 | -22% | -46% | -79% | $1,744,599.77 |
| NYR | Nyrada Inc. | 0.155 | -23% | -18% | -47% | $24,181,348.50 |
| 1ST | 1St Group Ltd | 0.007 | -30% | -30% | -63% | $3,879,076.66 |
| BPH | BPH Energy Ltd | 0.022 | -41% | -41% | -76% | $15,958,758.02 |
Analytica was the best healthcare performer in the last couple of weeks after announcing that its PeriCoach pelvic floor exercise system received patents grants in Europe and India.
In Europe, the patent was validated in Switzerland, France, Great Britain, Italy, Sweden, Turkey and Germany.
The invention has already been granted a patent in Australia and Japan.
Imugene said its Phase 1 clinical trial of cancer-killing virus CF33-hNIS VAXINIA has officially begun, with the dosing of the first patient.
Imugene and clinical partner City of Hope, a renowned cancer hospital in Los Angeles, said the Phase 1 trial will start by delivering a low dose of CF33-hNIS to cancer patients with metastatic or advanced solid tumours, who have had at least two prior standard of care treatments.
Imugene also released a letter to shareholders earlier this week, saying the company is as strong as it has ever been despite the share price falling by 53% this year.
In the letter, the company says it has not been immune to the recent turbulence in the market, but affirms that it’s fully funded with $100m in cash to weather the storm.
AnteoTech has successfully registered an updated EuGeni COVID-19 Rapid Antigen Test (RAT) in Europe.
Currently unavailable in Australia, the EuGeni is Aneteotech’s fast solution for rapid point-of-care testing.
With a small and portable benchtop design, it can be easily transported in the clinic and on the field for use by healthcare professionals.
The new European registration is for the same core SARS-CoV-2 Ag RAT registered in April of 2021, but now covers multiple use claims including combined nose and throat sampling.
Medibio confirmed the US FDA has confirmed the use of DSM-V Diagnostic Method for Medibio’s final depression validation trial.
Medibio’s clinical team proposed the International Neuropsychiatric Interview (MINI) as a diagnostic tool to satisfy the FDA’s request, whilst trying to minimise the burden of conduct for the validation trial.
The FDA has confirmed that the MINI can be used to support the trial clinician diagnosis.
Oneview has this week signed a deal with BJC Health System to provide Oneview’s platform to 2,441 additional beds.
The agreement represents a 20% increase under an existing contract with BCJ, which now takes the number of beds using Oneview’s platform to 14,283.
Under this agreement, BJC will also be migrating to Oneview’s CXP Cloud Enterprise platform, and moving all existing deployments to Android hardware.
Health & Biotech
Health & Biotech
Health & Biotech
Get the latest Stockhead news delivered free to your inbox.
